Oslo, Norway, 21 February 2024 - Photocure ASA (OSE:PHO) today reported
Hexvix[®]/Cysview[®] revenues of NOK 114.2 million in the fourth quarter of
2023, an increase of 20% over the prior-year period (Q4 2022: NOK 94.9 million),
and EBITDA of NOK 29.9 million (NOK -16.9 million) following solid business
development for the Company. Total revenues increased 37% in the fourth quarter
of 2023 compared to Q4 2022, including a milestone payment from Asieris related
to the license agreement for Cevira[®]. Photocure has an ambition to deliver 40
-70 new and upgraded SaphiraT tower installations in 2024, consolidated product
revenue growth of 6% to 9% (constant currency), and positive EBITDA excluding
business development expenses.

"Hexvix/Cysview revenue increased 20% year-over-year in the fourth quarter, and
we delivered EBITDA of NOK 29.9 million. Our U.S. business grew despite the
ongoing phase down of flexible BLC. In Europe, we continued to see positive
developments with sales growth in Germany and strong signs of traction in high
-potential underpenetrated territories, known as our Priority Growth Markets.
Additionally, our partner Asieris announced acceptance of their new drug
application for Hexvix in China, and that they plan to present the positive
Phase III results for Cevira at the EUROGIN 2024 HPV Congress in March,"  says
Dan Schneider, President & Chief Executive Officer of Photocure.

Photocure reported total group revenues of NOK 142.5 million in the fourth
quarter of 2023 (NOK 104.2 million), and EBITDA* of NOK 29.9 million (NOK -16.9
million), driven by a combination of unit volume growth, price increases and a
benefit from foreign exchange. Hexvix/Cysview revenues ended at NOK 114.2
million in the quarter (Q4 2022: NOK 94.9 million). EBIT was NOK 22.5 million
(NOK -23.1 million) and the cash balance at the end of the period was NOK 259.5
million.

At the end of the fourth quarter of 2023, the installed base of rigid blue light
cystoscopy (BLC[®]) systems in the U.S. was 352, an increase of 17% or 51 towers
since the fourth quarter of 2022. 2023 marked the highest number of rigid
cystoscopes placed during any year since Photocure launched BLC in the U.S.
SaphiraT blue light towers now represent 39% of the installed base of U.S. rigid
towers.

"We continue to expect a large order of new rigid towers to come through,
however, timing of the order is now anticipated in the second quarter of this
year. We believe deployment of these towers has potential to significantly
expand access to blue light cystoscopy for more physicians and patients in the
U.S. In addition, our commercial team in North America remains focused on
increasing Cysview kit usage in existing accounts, accelerating adoption in
accounts using Saphira for the first time, reactivating low users or inactive
accounts, and expanding BLC usage by leveraging the positive clinical results
from studies reported in 2023,"  Schneider adds.

Photocure believes that the benefits of Blue Light Cystoscopy with
Hexvix/Cysview offering superior detection and management of bladder cancer will
continue to be adopted and become the standard of care. For 2024, the Company
anticipates new and upgraded SaphiraT blue light tower installations in the U.S.
in the range of 40 to 70, consolidated product revenue growth of 6% to 9% in
constant currency, and positive EBITDA excluding business development expenses.

"This year, we are planning for further growth and are well-positioned for new
opportunities. We expect that the installed base of rigid towers in the U.S.
will continue to expand, augmented by a large potential order anticipated next
quarter. The technology upgrade cycle in blue light cystoscopy is expected to
continue with the anticipated launch of Olympus' new HD blue light system later
this year.  Also key to long term success is our strategy to reintroduce
flexible BLC in high definition so that we can further develop the large
surveillance market worldwide," Schneider continues, and concludes:

"The Citizen's Petition to reclassify BLC equipment from Class 3 to Class 2 in
the U.S. is a potential regulatory action that could change the game by creating
an accelerated approval process that would enable equipment manufacturers to
access the U.S. market quickly and expand BLC use by meeting the demands of the
market. Our partner Asieris continues to advance its licensed and partnered
programs: Cevira and Hexvix in China, respectively, which are both expected to
generate significant additional revenue through regulatory and future sales
milestones. With these initiatives and more, we look forward to the coming year.
We remain focused on driving value for patients, our customers and our
shareholders."

Please find the full financial report and presentation enclosed.

EBITDA* and other alternative performance measures (APMs) are defined and
reconciled to the IFRS financial statements as a part of the APM section of the
fourth quarter 2023 financial report on page 24.

The quarterly report and presentation will be published at 08:00 CET and will be
publicly available at www.photocure.com. Dan Schneider, CEO and Erik Dahl, CFO,
will host a live webcast at 14:00 CET.

The presentation will be held in English and questions can be submitted
throughout the event. The streaming event is available through
https://channel.royalcast.com/landingpage/hegnarmedia/20240221_5/

The presentation is scheduled to conclude at 14:45 CET.

For further information, please contact:
Dan Schneider
President and CEO
Photocure ASA
Tel: + 1-609 759-6515
Email: ds@photocure.com

Erik Dahl
Chief Financial Officer
Tel: +47 450 55 000
Email: ed@photocure.no

David Moskowitz
Vice President of Investor Relations
Tel: +1 202 280 0888
Email: david.moskowitz@photocure.com

Media and IR enquiries:
Geir Bjørlo
Corporate Communications (Norway)
Tel: +47 91540000
Email: geir.bjorlo@corpcom.no

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com, www.cysview.com

All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA.